local_hospital

Complejo Asistencial De Zamora Hospital Provincial De Zamora

Address
lock Available on a paid plan

Cardiovascular Diseases

At the Complejo Asistencial De Zamora Hospital Provincial De Zamora, researchers are exploring ways to reduce clotting complications in high‑risk patients, particularly focusing on venous thromboembolism prevention and the use of low‑molecular‑weight heparin in oncology settings.

  • Prophylaxis of clot formation in metastatic colorectal cancer patients
  • Evaluation of anticoagulant strategies during cancer therapy
  • Safety monitoring of long‑term anticoagulation

The surgical department collaborates closely with oncology to integrate cardiovascular risk management into comprehensive cancer care.

Digestive System Diseases

Clinical studies at the site aim to improve outcomes for gastrointestinal conditions, ranging from stage IV colon or rectal adenocarcinoma to symptomatic cholelithiasis, and include innovative imaging during laparoscopic cholecystectomy.

  • Targeted therapies for advanced colorectal tumors
  • Imaging techniques to enhance biliary visualization
  • Post‑operative recovery protocols after gallbladder surgery

Multidisciplinary teams work together to streamline surgical pathways and reduce postoperative complications.

Neoplasms

The hospital conducts research aimed at advancing treatment options for malignant tumors, with a particular emphasis on metastatic colorectal cancer and patient‑centered quality of life.

  • Combination chemotherapy and targeted agents
  • Quality‑of‑life assessments during cancer therapy
  • Biomarker discovery for treatment response

Oncology investigators partner with surgical colleagues to evaluate peri‑operative interventions for tumor control.

Nervous System Diseases

Investigations address disorders of the central nervous system, with a strong emphasis on treatment‑resistant schizophrenia and associated cognitive impairment.

  • Novel antipsychotic agents for refractory symptoms
  • Safety follow‑up after long‑term exposure
  • Cognitive function monitoring in chronic schizophrenia

The department’s neuro‑psychiatric expertise supports comprehensive care for patients with severe mental illness.

Behavior and Behavior Mechanisms

Research examines behavioral disturbances in neurodevelopmental and neurodegenerative conditions, seeking better management strategies for irritability associated with autistic disorder and agitation in Alzheimer’s disease.

  • Behavioral rating scales for autism
  • Intervention trials for agitation in dementia
  • Parent‑reported outcomes for irritability

Findings aim to reduce caregiver burden and improve daily functioning for affected individuals.

Mental Disorders

Trials target major mood and psychotic disorders, testing adjunctive therapies to enhance existing treatments for major depressive disorder with anhedonia, schizophrenia, and psychosis associated with Alzheimer’s disease.

  • Adjunctive antidepressant strategies for anhedonia
  • Antipsychotic augmentation in resistant schizophrenia
  • Psychosis mitigation in Alzheimer’s patients

The aim is to broaden therapeutic options and improve symptom control across a spectrum of mental health conditions.

Psychological Phenomena

The focus is on subjective experiences such as agitation associated with Alzheimer’s dementia and psychosis in Alzheimer’s disease, aiming to enhance patient comfort and reduce caregiver stress.

  • Non‑pharmacologic approaches to agitation
  • Medication safety in elderly with psychosis
  • Caregiver training for behavioral management

Researchers evaluate both drug and behavioral interventions to identify the most effective strategies.

General Clinical Research

Beyond disease‑specific studies, the department runs exploratory projects that bridge surgery, psychiatry, and oncology to enhance overall patient care, emphasizing multidisciplinary collaboration.

  • Cross‑specialty protocol development
  • Health‑outcome metrics across surgical procedures
  • Long‑term follow‑up registries

These initiatives support continuous improvement of clinical practice within the hospital.

Site Overview

assignment
19
connected trials
corporate_fare
14
sponsors
science
22
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
19
Total trials linked
Highly Active
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 8 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
11
Sponsors (total)
14
Active sponsors
9

Sponsor Network

Top 9 by active trials.

lock +8 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +2 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
19
Outperforms 79% of sites
public
Therapeutic diversity
8areas
Outperforms 82% of sites
groups
Sponsor diversity
14sponsors
Outperforms 80% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Complejo Asistencial De Zamora Hospital Provincial De Zamora

lock Showing 1 of 19 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.Otsuka Pharmaceutical Development & Commercialization Inc.Phase IVNot RecruitingMar 2023Nov 2025

IMP list

lock Showing 1 of 22 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Acp-204 Tartrate2Unknown2024-07-022024-12-03

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.